This week we finished a MARA Rating for a treatment for idiopathic pulmonary fibrosis — a progressive lung disease with limited options.

The Phase 3 trial answered one question clearly: does this treatment slow the loss of lung function? It does. The difference versus placebo was significant and consistent.

There is a second question the evidence was expected to answer: do patients feel better?

The quality-of-life instruments showed no significant improvement. No cost data has been published.

Two questions. The lung function question was answered. The patient experience question was not.

Read the full MARA Rating here: https://mararating.com/report/nerandomilast-for-n-a-as-of-february-2026/